Brokerages expect that Diplomat Pharmacy Inc (NYSE:DPLO) will report earnings per share (EPS) of $0.24 for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for Diplomat Pharmacy’s earnings, with estimates ranging from $0.22 to $0.27. Diplomat Pharmacy posted earnings per share of $0.18 during the same quarter last year, which would indicate a positive year over year growth rate of 33.3%. The company is expected to report its next quarterly earnings results after the market closes on Monday, February 25th.

On average, analysts expect that Diplomat Pharmacy will report full year earnings of $0.81 per share for the current fiscal year, with EPS estimates ranging from $0.78 to $0.84. For the next fiscal year, analysts forecast that the firm will report earnings of $0.86 per share, with EPS estimates ranging from $0.77 to $1.02. Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Diplomat Pharmacy.

Several equities analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Diplomat Pharmacy from a “hold” rating to a “strong sell” rating in a report on Tuesday, November 27th. ValuEngine downgraded shares of Diplomat Pharmacy from a “sell” rating to a “strong sell” rating in a report on Monday, February 4th. Mizuho dropped their target price on shares of Diplomat Pharmacy to $18.00 and set a “neutral” rating for the company in a report on Friday, November 9th. Wells Fargo & Co dropped their target price on shares of Diplomat Pharmacy from $23.00 to $16.00 and set a “market perform” rating for the company in a report on Thursday, November 8th. Finally, Robert W. Baird downgraded shares of Diplomat Pharmacy from a “neutral” rating to an “underperform” rating and dropped their target price for the company from $22.00 to $10.00 in a report on Wednesday, November 7th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $21.25.

A number of large investors have recently bought and sold shares of the business. Capital International Investors acquired a new stake in shares of Diplomat Pharmacy during the 3rd quarter worth about $99,092,000. Frontier Capital Management Co. LLC boosted its stake in shares of Diplomat Pharmacy by 84.1% during the 3rd quarter. Frontier Capital Management Co. LLC now owns 3,535,217 shares of the company’s stock worth $68,619,000 after purchasing an additional 1,614,645 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Diplomat Pharmacy by 17.0% during the 3rd quarter. BlackRock Inc. now owns 8,464,251 shares of the company’s stock worth $164,292,000 after purchasing an additional 1,228,490 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Diplomat Pharmacy by 97.5% during the 4th quarter. Bank of New York Mellon Corp now owns 1,682,590 shares of the company’s stock worth $22,648,000 after purchasing an additional 830,436 shares during the last quarter. Finally, Matarin Capital Management LLC acquired a new stake in shares of Diplomat Pharmacy during the 3rd quarter worth about $13,536,000. Hedge funds and other institutional investors own 81.89% of the company’s stock.

NYSE:DPLO traded up $0.32 during mid-day trading on Monday, hitting $13.42. 373,232 shares of the company’s stock traded hands, compared to its average volume of 648,846. The company has a current ratio of 0.95, a quick ratio of 0.66 and a debt-to-equity ratio of 0.58. Diplomat Pharmacy has a 1 year low of $12.30 and a 1 year high of $28.74. The company has a market capitalization of $989.71 million, a P/E ratio of 15.98 and a beta of 0.98.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Further Reading: How can investors find ex-dividend dates?

Get a free copy of the Zacks research report on Diplomat Pharmacy (DPLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.